



US011007166B2

(12) **United States Patent**
Novas et al.

(10) **Patent No.:** **US 11,007,166 B2**
(45) **Date of Patent:** ***May 18, 2021**

(54) **METHODS OF TREATING MULTIPLE SCLEROSIS**

(71) Applicant: **Biogen MA Inc.**, Cambridge, MA (US)

(72) Inventors: **Mark Novas**, Lexington, MA (US); **Rui (Ray) Zhang**, Sharon, MA (US)

(73) Assignee: **BIOGEN MA INC.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/936,398**

(22) Filed: **Jul. 22, 2020**

(65) **Prior Publication Data**

US 2020/0345679 A1 Nov. 5, 2020

Related U.S. Application Data

(63) Continuation of application No. 15/527,252, filed as application No. PCT/US2015/060850 on Nov. 16, 2015.

(60) Provisional application No. 62/232,963, filed on Sep. 25, 2015, provisional application No. 62/140,255, filed on Mar. 30, 2015, provisional application No. 62/080,783, filed on Nov. 17, 2014.

(51) **Int. Cl.**

A61K 31/225 (2006.01)

G01N 33/49 (2006.01)

A61K 47/54 (2017.01)

A61P 25/00 (2006.01)

A61K 9/00 (2006.01)

A61K 9/28 (2006.01)

A61K 9/48 (2006.01)

G09B 19/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/225** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/28** (2013.01); **A61K 9/485** (2013.01); **A61K 9/4808** (2013.01); **A61K 9/4825** (2013.01); **A61K 9/4858** (2013.01); **A61K 9/4866** (2013.01); **A61K 47/542** (2017.08); **A61K 47/545** (2017.08); **G01N 33/492** (2013.01); **G09B 19/00** (2013.01); **A61P 25/00** (2018.01); **Y02A 50/30** (2018.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,959,389 A	9/1990	Speiser et al.
6,436,992 B1	8/2002	Joshi et al.
6,509,376 B1	1/2003	Joshi et al.
8,148,414 B2	4/2012	Gangakhedkar et al.
8,669,281 B1	3/2014	Zeidan et al.
9,326,947 B1	5/2016	Dyakonov et al.
9,326,965 B2	5/2016	Dyakonov et al.
9,511,043 B2	12/2016	Dyakonov et al.
9,517,209 B2	12/2016	Dyakonov et al.
9,566,259 B1	2/2017	Vaughn et al.
9,636,318 B2	5/2017	Vaughn et al.
9,636,319 B1	5/2017	Vaughn et al.
9,814,691 B2	11/2017	Dyakonov et al.
9,814,692 B2	11/2017	Vaughn et al.
9,820,960 B2	11/2017	Dyakonov et al.
9,820,961 B2	11/2017	Vaughn et al.
10,098,863 B2	10/2018	Vaughn et al.
10,391,160 B2	8/2019	Viglietta
2007/0207141 A1	9/2007	Lieberburg
2010/0048651 A1	2/2010	Gangakhedkar et al.
2010/0130607 A1	5/2010	Gold
2013/0216615 A1	8/2013	Goldman et al.
2014/0057918 A1	2/2014	Wustrow et al.
2014/0179778 A1	6/2014	Mao et al.
2014/0179779 A1	6/2014	Chao
2014/0322251 A1*	10/2014	Ruff C07K 7/06 424/185.1
2015/0038499 A1	2/2015	Virsik
2017/0000873 A1	1/2017	Viglietta
2017/0354630 A1	12/2017	Novas et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	103732062 A	4/2014
JP	2009-528359 A	8/2009

(Continued)

OTHER PUBLICATIONS

Tecfidera FDA Prescribing Information (Mar. 27, 2013).*

(Continued)

Primary Examiner — Bong-Sook Baek

(74) *Attorney, Agent, or Firm* — Choate, Hall & Stewart LLP; Brenda Herschbach Jarrell; Tracy L. Vrablik

(57) **ABSTRACT**

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

16 Claims, 4 Drawing Sheets